JP2007511212A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007511212A5 JP2007511212A5 JP2006538818A JP2006538818A JP2007511212A5 JP 2007511212 A5 JP2007511212 A5 JP 2007511212A5 JP 2006538818 A JP2006538818 A JP 2006538818A JP 2006538818 A JP2006538818 A JP 2006538818A JP 2007511212 A5 JP2007511212 A5 JP 2007511212A5
- Authority
- JP
- Japan
- Prior art keywords
- adenovirus
- protein
- promoter
- nucleic acid
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000701161 unidentified adenovirus Species 0.000 claims 101
- 108090000623 proteins and genes Proteins 0.000 claims 68
- 102000004169 proteins and genes Human genes 0.000 claims 65
- 150000007523 nucleic acids Chemical class 0.000 claims 41
- 108020004707 nucleic acids Proteins 0.000 claims 35
- 102000039446 nucleic acids Human genes 0.000 claims 35
- 210000004027 cell Anatomy 0.000 claims 29
- 206010028980 Neoplasm Diseases 0.000 claims 20
- 230000010076 replication Effects 0.000 claims 19
- 239000003814 drug Substances 0.000 claims 14
- 101710199711 Early E1A protein Proteins 0.000 claims 13
- 229940079593 drug Drugs 0.000 claims 12
- 239000013598 vector Substances 0.000 claims 12
- 241000700605 Viruses Species 0.000 claims 11
- 239000003795 chemical substances by application Substances 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 230000001613 neoplastic effect Effects 0.000 claims 7
- 210000000056 organ Anatomy 0.000 claims 7
- 210000001519 tissue Anatomy 0.000 claims 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 6
- 239000000824 cytostatic agent Substances 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 3
- 230000022131 cell cycle Effects 0.000 claims 3
- 230000006037 cell lysis Effects 0.000 claims 3
- 230000001085 cytostatic effect Effects 0.000 claims 3
- 230000002074 deregulated effect Effects 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 230000005855 radiation Effects 0.000 claims 3
- 230000003362 replicative effect Effects 0.000 claims 3
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- JWOGUUIOCYMBPV-GMFLJSBRSA-N (3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone Chemical compound N1C(=O)[C@H](CCCCCC(=O)CC)NC(=O)[C@H]2CCCCN2C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-GMFLJSBRSA-N 0.000 claims 2
- BWDQBBCUWLSASG-MDZDMXLPSA-N (e)-n-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(CCO)CC1=CC=C(\C=C\C(=O)NO)C=C1 BWDQBBCUWLSASG-MDZDMXLPSA-N 0.000 claims 2
- 241000283690 Bos taurus Species 0.000 claims 2
- 241000282472 Canis lupus familiaris Species 0.000 claims 2
- 241000283707 Capra Species 0.000 claims 2
- 241000700198 Cavia Species 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 241000283086 Equidae Species 0.000 claims 2
- 241000282326 Felis catus Species 0.000 claims 2
- 108010033040 Histones Proteins 0.000 claims 2
- 241000699670 Mus sp. Species 0.000 claims 2
- JWOGUUIOCYMBPV-UHFFFAOYSA-N OT-Key 11219 Natural products N1C(=O)C(CCCCCC(=O)CC)NC(=O)C2CCCCN2C(=O)C(C(C)CC)NC(=O)C1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-UHFFFAOYSA-N 0.000 claims 2
- 241001494479 Pecora Species 0.000 claims 2
- 241000700159 Rattus Species 0.000 claims 2
- 241000282887 Suidae Species 0.000 claims 2
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 2
- 108010082820 apicidin Proteins 0.000 claims 2
- 229930186608 apicidin Natural products 0.000 claims 2
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 claims 2
- 229960003094 belinostat Drugs 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000001276 controlling effect Effects 0.000 claims 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 2
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 229960004768 irinotecan Drugs 0.000 claims 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 2
- 108700026220 vif Genes Proteins 0.000 claims 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- FUXVKZWTXQUGMW-FQEVSTJZSA-N 9-Aminocamptothecin Chemical compound C1=CC(N)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 FUXVKZWTXQUGMW-FQEVSTJZSA-N 0.000 claims 1
- 108010057856 Adenovirus E2 Proteins Proteins 0.000 claims 1
- 108091023037 Aptamer Proteins 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 206010061968 Gastric neoplasm Diseases 0.000 claims 1
- 206010019695 Hepatic neoplasm Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 206010020843 Hyperthermia Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010029098 Neoplasm skin Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- 206010062129 Tongue neoplasm Diseases 0.000 claims 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 claims 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 claims 1
- 108010067390 Viral Proteins Proteins 0.000 claims 1
- 210000004102 animal cell Anatomy 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 229940127093 camptothecin Drugs 0.000 claims 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000005616 epidermal appendage tumor Diseases 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 230000036031 hyperthermia Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 206010023841 laryngeal neoplasm Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 230000010534 mechanism of action Effects 0.000 claims 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims 1
- 208000025402 neoplasm of esophagus Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 208000023958 prostate neoplasm Diseases 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 claims 1
- 229950009213 rubitecan Drugs 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 201000008753 synovium neoplasm Diseases 0.000 claims 1
- 201000006134 tongue cancer Diseases 0.000 claims 1
- 229960000303 topotecan Drugs 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
- 208000025421 tumor of uterus Diseases 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10353152 | 2003-11-14 | ||
| DE102004018117 | 2004-04-14 | ||
| PCT/EP2004/012931 WO2005052143A2 (de) | 2003-11-14 | 2004-11-15 | Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011098213A Division JP5618896B2 (ja) | 2003-11-14 | 2011-04-26 | 新規アデノウイルス、それをコードする核酸及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007511212A JP2007511212A (ja) | 2007-05-10 |
| JP2007511212A5 true JP2007511212A5 (enExample) | 2008-01-10 |
Family
ID=34635104
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006538818A Pending JP2007511212A (ja) | 2003-11-14 | 2004-11-15 | 新規アデノウイルス、それをコードする核酸及びその使用 |
| JP2011098213A Expired - Fee Related JP5618896B2 (ja) | 2003-11-14 | 2011-04-26 | 新規アデノウイルス、それをコードする核酸及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011098213A Expired - Fee Related JP5618896B2 (ja) | 2003-11-14 | 2011-04-26 | 新規アデノウイルス、それをコードする核酸及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20060270016A1 (enExample) |
| EP (1) | EP1689446B1 (enExample) |
| JP (2) | JP2007511212A (enExample) |
| CA (1) | CA2590257A1 (enExample) |
| WO (1) | WO2005052143A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1655827B (zh) | 2002-05-27 | 2010-06-23 | 佩尔·松内·霍尔姆 | 腺病毒和编码其的核酸的新应用 |
| WO2005051430A1 (de) | 2003-11-14 | 2005-06-09 | Per Sonne Holm | Neue verwendung von adenoviren und dafür codierenden nukleinsäuren |
| EP1830864A2 (de) * | 2004-12-31 | 2007-09-12 | Per Sonne Holm | E1 -minus adenoviren und deren verwendung |
| AU2006203736B2 (en) * | 2004-12-31 | 2012-03-29 | Per Sonne Holm | Method for reversing multiple resistance in animal cells |
| CA2596210C (en) | 2005-02-03 | 2014-07-08 | Topotarget Uk Limited | Combination therapies using hdac inhibitors |
| ES2380887T3 (es) | 2005-05-13 | 2012-05-21 | Topotarget Uk Limited | Formulaciones farmacéuticas de inhibidores de la HDAC |
| US8828392B2 (en) * | 2005-11-10 | 2014-09-09 | Topotarget Uk Limited | Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent |
| US20070129290A1 (en) * | 2005-11-18 | 2007-06-07 | Or Yat S | Metabolite derivatives of the HDAC inhibitor FK228 |
| EP2049139A4 (en) | 2006-04-24 | 2009-06-24 | Gloucester Pharmaceuticals Inc | TREATMENT OF TUMORS EXPRESSING RAS |
| WO2007146730A2 (en) * | 2006-06-08 | 2007-12-21 | Gloucester Pharmaceuticals | Deacetylase inhibitor therapy |
| BRPI0720734A2 (pt) * | 2006-12-29 | 2014-01-07 | Gloucester Pharmaceuticals Inc | Preparação da romidepsina |
| EP2102230A2 (en) * | 2006-12-29 | 2009-09-23 | Gloucester Pharmaceuticals, Inc. | Purifiction of romidepsin |
| WO2008136213A1 (ja) * | 2007-04-27 | 2008-11-13 | Oncolys Biopharma Inc. | 放射線増感増強剤 |
| EP2203421B1 (en) * | 2007-09-25 | 2014-05-07 | TopoTarget UK Limited | Methods of synthesis of certain n-hydroxy-3-(3-phenylsulfamoyl-phenyl)-acrylamide compounds |
| US20110003777A1 (en) * | 2008-03-07 | 2011-01-06 | Topotarget A/S | Methods of Treatment Employing Prolonged Continuous Infusion of Belinostat |
| GB0900555D0 (en) * | 2009-01-14 | 2009-02-11 | Topotarget As | New methods |
| PT2403951E (pt) | 2009-03-02 | 2016-01-29 | Univ California | Mutantes de adenovírus e1a e e1b de tumores |
| AU2011279303B2 (en) | 2010-07-12 | 2015-07-16 | Celgene Corporation | Romidepsin solid forms and uses thereof |
| US8859502B2 (en) | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
| AU2013202506B2 (en) | 2012-09-07 | 2015-06-18 | Celgene Corporation | Resistance biomarkers for hdac inhibitors |
| AU2013202507B9 (en) | 2012-11-14 | 2015-08-13 | Celgene Corporation | Inhibition of drug resistant cancer cells |
| NZ630311A (en) | 2013-12-27 | 2016-03-31 | Celgene Corp | Romidepsin formulations and uses thereof |
| CN109576231B (zh) * | 2017-09-28 | 2022-03-25 | 北京康万达医药科技有限公司 | 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 |
| CA3092907A1 (en) * | 2018-03-05 | 2019-09-12 | Klinikum Rechts Der Isar Der Technischen Universitat Munchen | Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor |
| EP3810638A1 (en) * | 2018-06-25 | 2021-04-28 | Ospedale San Raffaele S.r.l. | Gene therapy |
| US20220370464A1 (en) * | 2019-06-25 | 2022-11-24 | Microbiotix, Inc. | Compositions and methods of treating or preventing ocular infections with filociclovir |
| CN116179604B (zh) * | 2022-08-31 | 2025-08-26 | 上海锦斯生物技术有限公司 | 一种降低回复突变频率的重组5型腺病毒载体及其构建方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995034671A1 (en) | 1994-06-10 | 1995-12-21 | Genvec, Inc. | Complementary adenoviral vector systems and cell lines |
| US5998205A (en) * | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| DE19929569A1 (de) * | 1999-06-21 | 2000-12-28 | Holm Per Sonne | Mittel zur Behandlung maligner Erkrankungen unter Verwendung des Proteins YB-1 |
| US20030095989A1 (en) * | 2000-12-18 | 2003-05-22 | Irving John M. | Chimeric cytolytic viruses for cancer treatment |
| DE10150945A1 (de) * | 2001-10-16 | 2003-04-17 | Holm Per Sonne | Adenovirale Systeme und deren Anwendungen |
| AU2002229679B2 (en) * | 2000-12-28 | 2007-12-20 | Per Sonne Holm | Use of transcription factor YB-1 in adenoviral systems |
| CN1655827B (zh) * | 2002-05-27 | 2010-06-23 | 佩尔·松内·霍尔姆 | 腺病毒和编码其的核酸的新应用 |
| JP4988199B2 (ja) * | 2002-10-15 | 2012-08-01 | ホルム，ペル・ゾンネ | 新規アデノウイルス、それをコードする核酸及びその使用 |
-
2004
- 2004-11-15 US US10/579,543 patent/US20060270016A1/en not_active Abandoned
- 2004-11-15 CA CA002590257A patent/CA2590257A1/en not_active Abandoned
- 2004-11-15 EP EP04803146.2A patent/EP1689446B1/de not_active Expired - Lifetime
- 2004-11-15 WO PCT/EP2004/012931 patent/WO2005052143A2/de not_active Ceased
- 2004-11-15 JP JP2006538818A patent/JP2007511212A/ja active Pending
-
2010
- 2010-01-20 US US12/690,729 patent/US8586354B2/en not_active Expired - Fee Related
-
2011
- 2011-04-26 JP JP2011098213A patent/JP5618896B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007511212A5 (enExample) | ||
| Roth et al. | Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity | |
| Gieniec et al. | Cancer-associated fibroblasts—heroes or villains? | |
| JP6956159B2 (ja) | 腫瘍溶解性アデノウイルスによる脳癌の処置方法 | |
| Liang et al. | The use of folate-PEG-grafted-hybranched-PEI nonviral vector for the inhibition of glioma growth in the rat | |
| Stuckey et al. | Stem cell-based therapies for cancer treatment: separating hope from hype | |
| Spitzweg et al. | The sodium iodide symporter (NIS): novel applications for radionuclide imaging and treatment | |
| JP2007511507A (ja) | 癌を処置するための治療レジメン | |
| JP2017519039A5 (enExample) | ||
| JP2008526188A5 (enExample) | ||
| EA028590B1 (ru) | Ингибиторы мет для повышения эффективности лучевой терапии | |
| CN112672739A (zh) | 治疗癌症的方法 | |
| JP2005536447A (ja) | Ｔｎｆ−アルファを発現するアデノウイルスベクターを用いるヒト癌の処置 | |
| JP2008526189A5 (enExample) | ||
| JP2006512284A5 (enExample) | ||
| Kuroda et al. | Selectively replicating oncolytic adenoviruses combined with chemotherapy, radiotherapy, or molecular targeted therapy for treatment of human cancers | |
| Goklany et al. | Delivery of TRAIL-expressing plasmid DNA to cancer cells in vitro and in vivo using aminoglycoside-derived polymers | |
| JP2006518589A5 (enExample) | ||
| ES2800162T3 (es) | Uso terapéutico de moduladores funcionales negativos de la eritropoyetina | |
| CA3028934C (en) | Agent for inducing cell death, agent for suppressing cell proliferation, and pharmaceutical composition used for treatment of disease resulting from abnormal cell proliferation | |
| Hervé et al. | Internal radiotherapy of liver cancer with rat hepatocarcinoma-intestine-pancreas gene as a liver tumor-specific promoter | |
| JP6803619B2 (ja) | ＲＥＩＣ／Ｄｋｋ−３遺伝子およびチェックポイント阻害剤を用いた併用療法 | |
| RU2005114516A (ru) | Аденовирус с обращенной генной экспрессией и его применение | |
| WO2016066671A1 (en) | Method for treating resistant cancers using progastrin inhibitors | |
| WO2018064513A1 (en) | Natural killer cell-evasive oncolytic viruses |